Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43860   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who Have Received Prior Trastuzumab and Taxane Based Therapy

    Summary
    EudraCT number
    		 2015-004189-27
    Trial protocol
    		 DE   ES   GB   IT  
    Global end of trial date
    06 Feb 2020

    Results information
    Results version number
    		 v2(current)
    This version publication date
    14 Feb 2021
    First version publication date
    26 Dec 2018
    Other versions
    		 v1
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    WO30085
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT02924883
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    F. Hoffmann-La Roche AG
    Sponsor organisation address
    Grenzacherstrasse 124, Basel, Switzerland, CH-4070
    Public contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Scientific contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    06 Feb 2020
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    06 Feb 2020
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    This Phase II, double-blind, randomized, placebo-controlled multicenter study investigated the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with HER2-positive locally advanced or metastatic BC who have received prior trastuzumab and taxane based therapy, either alone or in combination, and/or who have progressed within 6 months after completing adjuvant therapy.
    Protection of trial subjects
    All study subjects were required to read and sign an Informed Consent Form.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    26 Sep 2016
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    		 Efficacy, Safety
    Long term follow-up duration
    		 24 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 21
    Country: Number of subjects enrolled
    Germany: 16
    Country: Number of subjects enrolled
    Italy: 21
    Country: Number of subjects enrolled
    Canada: 16
    Country: Number of subjects enrolled
    Australia: 15
    Country: Number of subjects enrolled
    Korea, Republic of: 39
    Country: Number of subjects enrolled
    Taiwan: 24
    Country: Number of subjects enrolled
    United States: 32
    Country: Number of subjects enrolled
    United Kingdom: 18
    Worldwide total number of subjects
    202
    EEA total number of subjects
    58
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    176
    From 65 to 84 years
    26
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 Approximately 200 patients were enrolled and randomized to both treatment arms in a 1:2 ratio.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Trastuzumab Emtansine + Placebo
    Arm description
    		 Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 40 months)
    Arm type
    		 Active comparator

    Investigational medicinal product name
    Trastuzumab Emtansine
    Investigational medicinal product code
    Other name
    Kadcyla
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Trastuzumab emtansine was administered 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Placebo (matching to atezolizumab) was administered by IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.

    Arm title
    		 Trastuzumab Emtansine + Atezolizumab
    Arm description
    		 Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 40 months)
    Arm type
    		 Experimental

    Investigational medicinal product name
    Atezolizumab
    Investigational medicinal product code
    Other name
    Tecentriq
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Atezolizumab 1200 mg was administered by IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.

    Investigational medicinal product name
    Trastuzumab Emtansine
    Investigational medicinal product code
    Other name
    Kadcyla
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Trastuzumab emtansine was administered 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.

    Number of subjects in period 1
    		Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Started
    69
    133
    Completed
    0
    0
    Not completed
    69
    133
         Consent withdrawn by subject
    16
    22
         Death
    20
    39
         Progressive Disease
    -
    1
         Study Terminated by Sponsor
    32
    69
         Symptomatic deterioration/clinical progression
    1
    -
         Lost to follow-up
    -
    1
         Protocol deviation
    -
    1

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Trastuzumab Emtansine + Placebo
    Reporting group description
    		 Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 40 months)

    Reporting group title
    Trastuzumab Emtansine + Atezolizumab
    Reporting group description
    		 Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 40 months)

    Reporting group values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab Total
    Number of subjects
    		 69 133 202
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 58 118 176
        From 65-84 years
    		 11 15 26
        85 years and over
    		 0 0 0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 54.4 ± 10.9 53.7 ± 9.9 -
    Sex: Female, Male
    Units: Subjects
        Female
    		 69 131 200
        Male
    		 0 2 2
    Race (NIH/OMB)
    Units: Subjects
        Asian
    		 23 49 72
        Black or African American
    		 1 5 6
        Native Hawaiian or other Pacific Islander
    		 0 1 1
        White
    		 44 72 116
        Multiple
    		 0 1 1
        Unknown
    		 1 5 6
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    		 1 10 11
        Not Hispanic or Latino
    		 66 114 180
        Not Stated
    		 1 4 5
        Unknown
    		 1 5 6

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Trastuzumab Emtansine + Placebo
    Reporting group description
    		 Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 40 months)

    Reporting group title
    Trastuzumab Emtansine + Atezolizumab
    Reporting group description
    		 Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 40 months)

    Primary: Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)

    		 Close Top of page
    End point title
    		 Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)
    End point description
    PFS was defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions.
    End point type
    Primary
    End point timeframe
    Baseline up to clinical cut off date (11 Dec 2017)
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    69
    133
    Units: months
        median (confidence interval 95%)
    6.8 (4.0 to 11.1)
    8.2 (5.8 to 10.7)
    Statistical analysis title
    		 Progression-Free Survival
    Comparison groups
    Trastuzumab Emtansine + Placebo v Trastuzumab Emtansine + Atezolizumab
    Number of subjects included in analysis
    202
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.3332
    Method
    		 Logrank
    Parameter type
    		 Hazard ratio (HR)
    Point estimate
    0.82
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.55
         upper limit
    		 1.23

    Primary: Percentage of Subjects with Adverse Events

    		 Close Top of page
    End point title
    		 Percentage of Subjects with Adverse Events [1]
    End point description
    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
    End point type
    Primary
    End point timeframe
    Baseline up to study completion, approximately 40 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This is the primary safety endpoint. Typically statistical testing is only applied to efficacy endpoints, and for safety endpoints only summary statistics will be provided.
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    68
    132
    Units: Percentage of subjects
        number (not applicable)
    97.0
    99.2
    No statistical analyses for this end point

    Secondary: Overall Survival (OS)

    		 Close Top of page
    End point title
    		 Overall Survival (OS)
    End point description
    OS was defined as the time from randomization to death from any cause. 9999 = Median and corresponding 95% CI could not be estimated as too few participants had an event.
    End point type
    Secondary
    End point timeframe
    Baseline up to study completion or death, whichever occurs first, approximately 40 months
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    69
    133
    Units: Months
        median (confidence interval 95%)
    9999 (9999 to 9999)
    9999 (9999 to 9999)
    Statistical analysis title
    		 Overall Survival
    Comparison groups
    Trastuzumab Emtansine + Placebo v Trastuzumab Emtansine + Atezolizumab
    Number of subjects included in analysis
    202
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2934
    Method
    		 Logrank
    Parameter type
    		 Hazard ratio (HR)
    Point estimate
    0.74
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.42
         upper limit
    		 1.3

    Secondary: Percentage of Subjects With Objective Response (OR) as Determined by Investigator's Tumor Assessment Using RECIST v1.1

    		 Close Top of page
    End point title
    		 Percentage of Subjects With Objective Response (OR) as Determined by Investigator's Tumor Assessment Using RECIST v1.1
    End point description
    An OR was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be < 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum. Participants who had no post-baseline tumor assessment were counted as non-responders.
    End point type
    Secondary
    End point timeframe
    Baseline up to approximately 15 months
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    69
    132
    Units: Percentage of subjects
        number (not applicable)
    43.5
    45.5
    No statistical analyses for this end point

    Secondary: Duration of OR as Determined by Investigator's Tumor Assessment Using RECIST v1.1

    		 Close Top of page
    End point title
    		 Duration of OR as Determined by Investigator's Tumor Assessment Using RECIST v1.1
    End point description
    Duration of OR was defined as the time from the first tumor assessment that was judged to indicate that the patient had an objective response to the time of first documented disease progression using RECIST v1.1 per investigator assessment or death from any cause, whichever occurred first. 9999 = Median and upper bound of 95% CI could not be estimated as too few participants had an event.
    End point type
    Secondary
    End point timeframe
    Baseline up to approximately 15 months
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    69
    133
    Units: Months
        median (confidence interval 95%)
    9999 (9.9 to 9999)
    9999 (7.1 to 9999)
    Statistical analysis title
    		 Duration of Objective Response
    Comparison groups
    Trastuzumab Emtansine + Placebo v Trastuzumab Emtansine + Atezolizumab
    Number of subjects included in analysis
    202
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6099
    Method
    		 Logrank
    Parameter type
    		 Hazard ratio (HR)
    Point estimate
    1.26
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.52
         upper limit
    		 3.03

    Secondary: Maximum Serum Concentration (Cmax) of Trastuzumab Emtansine

    		 Close Top of page
    End point title
    		 Maximum Serum Concentration (Cmax) of Trastuzumab Emtansine
    End point description
    Average post infusion Trastuzumab Emtansine concentration.
    End point type
    Secondary
    End point timeframe
    Pre-infusion (0 hour [h]), 30 minutes (min) after end of infusion (EOI) (over 90 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycle 2 (each cycle = 21 days); at any time during study treatment/early discontinuation visit (approx. 40 months)
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    50
    110
    Units: ug/mL
        geometric mean (geometric coefficient of variation)
    73.2 ± 47.5
    63.9 ± 116.9
    No statistical analyses for this end point

    Secondary: Cmax of Deacetyl Mercapto 1-Oxopropyl Maytansine (DM1)

    		 Close Top of page
    End point title
    		 Cmax of Deacetyl Mercapto 1-Oxopropyl Maytansine (DM1)
    End point description
    Average post infusion Deacetyl Mercapto 1-Oxopropyl Maytansine concentration of trastuzumab emtansine infusion
    End point type
    Secondary
    End point timeframe
    Pre-infusion (0 h) on Day 1 Cycle 1 and 30 min after EOI (over 90 min) on Day 1 Cycles 1 and 4 (each cycle = 21 days)
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    24
    37
    Units: ng/mL
        geometric mean (geometric coefficient of variation)
    3.19 ± 84.7
    4.21 ± 89.5
    No statistical analyses for this end point

    Secondary: Cmax of Total Trastuzumab

    		 Close Top of page
    End point title
    		 Cmax of Total Trastuzumab
    End point description
    End point type
    Secondary
    End point timeframe
    Pre-infusion (0 h), 30 min after EOI (over 90 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycle 2 (each cycle = 21 days)
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    50
    110
    Units: ug/mL
        geometric mean (geometric coefficient of variation)
    86.5 ± 26.4
    79.5 ± 58.3
    No statistical analyses for this end point

    Secondary: Cmax of Atezolizumab

    		 Close Top of page
    End point title
    		 Cmax of Atezolizumab [2]
    End point description
    End point type
    Secondary
    End point timeframe
    Pre-infusion (0 h), 30 min after EOI (over 60 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycles 2, 3, 8, and every 8 cycles thereafter (each cycle=21 days) up to 120 days after treatment completion/early discontinuation (approx. 40 months)
    Notes
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Atezolizumab was being analyzed and thus is only applicable to the arm in which it was administered.
    End point values
    		 Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    98
    Units: ug/mL
        geometric mean (geometric coefficient of variation)
    626 ± 23.0
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Anti-therapeutic Antibodies (ATAs) to Atezolizumab

    		 Close Top of page
    End point title
    		 Percentage of Participants With Anti-therapeutic Antibodies (ATAs) to Atezolizumab [3]
    End point description
    ATAs are antibodies that inactivate the therapeutic effects of Atezolizumab. Patients are considered to be ATA positive if they are ATA negative at baseline but develop an ATA response following study drug administration (treatment-induced ATA response), or if they are ATA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater (i.e., ≥ 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ATA response).
    End point type
    Secondary
    End point timeframe
    Pre-infusion (0 h) on Day 1 Cycles 1, 2, 3, 4, 8, and every 8 cycles thereafter (each cycle = 21 days) up to 120 days after treatment completion or early discontinuation (approximately 40 months)
    Notes
    [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Atezolizumab was being analyzed and thus is only applicable to the arm in which it was administered.
    End point values
    		 Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    131
    Units: Percentage of participants
        number (not applicable)
    18.3
    No statistical analyses for this end point

    Secondary: Percentage of Participants With ATAs to Trastuzumab Emtansine

    		 Close Top of page
    End point title
    		 Percentage of Participants With ATAs to Trastuzumab Emtansine
    End point description
    ATAs are antibodies that inactivate the therapeutic effects of Trastuzumab Emtansine. Patients are considered to be ATA positive if they are ATA negative at baseline but develop an ATA response following study drug administration (treatment-induced ATA response), or if they are ATA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater (i.e., ≥ 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ATA response).
    End point type
    Secondary
    End point timeframe
    Pre-infusion (0 h) on Day 1 Cycles 1 and 4 (each cycle = 21 days); and at any time during study treatment/early discontinuation visit (approximately 40 months)
    End point values
    		 Trastuzumab Emtansine + Placebo Trastuzumab Emtansine + Atezolizumab
    Number of subjects analysed
    60
    129
    Units: Percentage of Participants
        number (not applicable)
    0
    2.3
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Baseline up to study completion, approximately 40 months
    Adverse event reporting additional description
    The safety population is defined as all participants who received at least one dose of the study medication.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    22.1
    Reporting groups
    Reporting group title
    Trastuzumab Emtansine + Atezolizumab
    Reporting group description
    		 Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (up to study duration of approximately 40 months)

    Reporting group title
    Trastuzumab Emtansine + Placebo
    Reporting group description
    		 Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (up to study duration of approximately 40 months)

    Serious adverse events
    		 Trastuzumab Emtansine + Atezolizumab Trastuzumab Emtansine + Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    52 / 133 (39.10%)
    16 / 67 (23.88%)
         number of deaths (all causes)
    42
    22
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Cancer pain
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic adenoma
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine leiomyoma
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    10 / 133 (7.52%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    9 / 12
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fatigue
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza like illness
         subjects affected / exposed
    2 / 133 (1.50%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune system disorders
    Haemophagocytic lymphohistiocytosis
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pneumonitis
         subjects affected / exposed
    2 / 133 (1.50%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    1 / 133 (0.75%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Panic attack
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    3 / 133 (2.26%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    3 / 133 (2.26%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Hip fracture
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower limb fracture
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subdural haemorrhage
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Atrial thrombosis
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Nervous system disorders
    Seizure
         subjects affected / exposed
    1 / 133 (0.75%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Brain oedema
         subjects affected / exposed
    2 / 133 (1.50%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Encephalopathy
         subjects affected / exposed
    1 / 133 (0.75%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neuropathy peripheral
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    2 / 133 (1.50%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Disseminated intravascular coagulation
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    3 / 133 (2.26%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    2 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    1 / 133 (0.75%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enteritis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 133 (0.00%)
    2 / 67 (2.99%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intra-abdominal haemorrhage
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    IgA nephropathy
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Osteonecrosis of jaw
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pathological fracture
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    4 / 133 (3.01%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    2 / 133 (1.50%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abscess jaw
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Breast cellulitis
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Catheter site infection
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infectious pleural effusion
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 133 (0.75%)
    2 / 67 (2.99%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Soft tissue infection
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    3 / 133 (2.26%)
    2 / 67 (2.99%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Decreased appetite
         subjects affected / exposed
    1 / 133 (0.75%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Trastuzumab Emtansine + Atezolizumab Trastuzumab Emtansine + Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    130 / 133 (97.74%)
    62 / 67 (92.54%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    4 / 133 (3.01%)
    4 / 67 (5.97%)
         occurrences all number
    4
    4
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    23 / 133 (17.29%)
    5 / 67 (7.46%)
         occurrences all number
    35
    6
    Chills
         subjects affected / exposed
    19 / 133 (14.29%)
    6 / 67 (8.96%)
         occurrences all number
    27
    8
    Fatigue
         subjects affected / exposed
    53 / 133 (39.85%)
    30 / 67 (44.78%)
         occurrences all number
    87
    43
    Pyrexia
         subjects affected / exposed
    44 / 133 (33.08%)
    12 / 67 (17.91%)
         occurrences all number
    72
    18
    Influenza like illness
         subjects affected / exposed
    12 / 133 (9.02%)
    8 / 67 (11.94%)
         occurrences all number
    16
    8
    Mucosal inflammation
         subjects affected / exposed
    16 / 133 (12.03%)
    1 / 67 (1.49%)
         occurrences all number
    21
    1
    Oedema peripheral
         subjects affected / exposed
    7 / 133 (5.26%)
    4 / 67 (5.97%)
         occurrences all number
    9
    4
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    25 / 133 (18.80%)
    10 / 67 (14.93%)
         occurrences all number
    28
    12
    Dyspnoea
         subjects affected / exposed
    16 / 133 (12.03%)
    5 / 67 (7.46%)
         occurrences all number
    19
    6
    Epistaxis
         subjects affected / exposed
    28 / 133 (21.05%)
    10 / 67 (14.93%)
         occurrences all number
    39
    13
    Oropharyngeal pain
         subjects affected / exposed
    7 / 133 (5.26%)
    1 / 67 (1.49%)
         occurrences all number
    8
    1
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    2 / 133 (1.50%)
    6 / 67 (8.96%)
         occurrences all number
    2
    6
    Insomnia
         subjects affected / exposed
    14 / 133 (10.53%)
    2 / 67 (2.99%)
         occurrences all number
    15
    2
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    31 / 133 (23.31%)
    13 / 67 (19.40%)
         occurrences all number
    44
    18
    Aspartate aminotransferase increased
         subjects affected / exposed
    40 / 133 (30.08%)
    14 / 67 (20.90%)
         occurrences all number
    56
    19
    Blood alkaline phosphatase increased
         subjects affected / exposed
    11 / 133 (8.27%)
    6 / 67 (8.96%)
         occurrences all number
    12
    8
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    7 / 133 (5.26%)
    2 / 67 (2.99%)
         occurrences all number
    7
    2
    Weight decreased
         subjects affected / exposed
    13 / 133 (9.77%)
    3 / 67 (4.48%)
         occurrences all number
    13
    3
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    10 / 133 (7.52%)
    3 / 67 (4.48%)
         occurrences all number
    14
    9
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    18 / 133 (13.53%)
    9 / 67 (13.43%)
         occurrences all number
    18
    10
    Dysgeusia
         subjects affected / exposed
    6 / 133 (4.51%)
    5 / 67 (7.46%)
         occurrences all number
    6
    6
    Headache
         subjects affected / exposed
    38 / 133 (28.57%)
    17 / 67 (25.37%)
         occurrences all number
    62
    27
    Paraesthesia
         subjects affected / exposed
    9 / 133 (6.77%)
    2 / 67 (2.99%)
         occurrences all number
    16
    2
    Neuropathy peripheral
         subjects affected / exposed
    18 / 133 (13.53%)
    7 / 67 (10.45%)
         occurrences all number
    20
    8
    Peripheral sensory neuropathy
         subjects affected / exposed
    11 / 133 (8.27%)
    5 / 67 (7.46%)
         occurrences all number
    11
    6
    Polyneuropathy
         subjects affected / exposed
    2 / 133 (1.50%)
    4 / 67 (5.97%)
         occurrences all number
    2
    4
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    24 / 133 (18.05%)
    6 / 67 (8.96%)
         occurrences all number
    30
    7
    Neutropenia
         subjects affected / exposed
    13 / 133 (9.77%)
    4 / 67 (5.97%)
         occurrences all number
    21
    4
    Thrombocytopenia
         subjects affected / exposed
    42 / 133 (31.58%)
    12 / 67 (17.91%)
         occurrences all number
    105
    22
    Eye disorders
    Dry eye
         subjects affected / exposed
    11 / 133 (8.27%)
    4 / 67 (5.97%)
         occurrences all number
    12
    4
    Lacrimation increased
         subjects affected / exposed
    7 / 133 (5.26%)
    1 / 67 (1.49%)
         occurrences all number
    9
    1
    Vision blurred
         subjects affected / exposed
    7 / 133 (5.26%)
    1 / 67 (1.49%)
         occurrences all number
    8
    1
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    29 / 133 (21.80%)
    10 / 67 (14.93%)
         occurrences all number
    38
    15
    Diarrhoea
         subjects affected / exposed
    34 / 133 (25.56%)
    15 / 67 (22.39%)
         occurrences all number
    50
    18
    Dyspepsia
         subjects affected / exposed
    14 / 133 (10.53%)
    3 / 67 (4.48%)
         occurrences all number
    21
    3
    Nausea
         subjects affected / exposed
    51 / 133 (38.35%)
    29 / 67 (43.28%)
         occurrences all number
    84
    37
    Stomatitis
         subjects affected / exposed
    13 / 133 (9.77%)
    2 / 67 (2.99%)
         occurrences all number
    21
    2
    Vomiting
         subjects affected / exposed
    27 / 133 (20.30%)
    15 / 67 (22.39%)
         occurrences all number
    36
    19
    Abdominal pain
         subjects affected / exposed
    17 / 133 (12.78%)
    3 / 67 (4.48%)
         occurrences all number
    20
    3
    Abdominal pain upper
         subjects affected / exposed
    10 / 133 (7.52%)
    3 / 67 (4.48%)
         occurrences all number
    10
    8
    Dry mouth
         subjects affected / exposed
    22 / 133 (16.54%)
    9 / 67 (13.43%)
         occurrences all number
    23
    10
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    23 / 133 (17.29%)
    4 / 67 (5.97%)
         occurrences all number
    30
    5
    Rash
         subjects affected / exposed
    32 / 133 (24.06%)
    6 / 67 (8.96%)
         occurrences all number
    42
    11
    Dry skin
         subjects affected / exposed
    11 / 133 (8.27%)
    0 / 67 (0.00%)
         occurrences all number
    12
    0
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    18 / 133 (13.53%)
    3 / 67 (4.48%)
         occurrences all number
    19
    3
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    26 / 133 (19.55%)
    8 / 67 (11.94%)
         occurrences all number
    37
    9
    Myalgia
         subjects affected / exposed
    24 / 133 (18.05%)
    10 / 67 (14.93%)
         occurrences all number
    26
    16
    Back pain
         subjects affected / exposed
    15 / 133 (11.28%)
    8 / 67 (11.94%)
         occurrences all number
    19
    9
    Bone pain
         subjects affected / exposed
    8 / 133 (6.02%)
    3 / 67 (4.48%)
         occurrences all number
    8
    8
    Muscle spasms
         subjects affected / exposed
    10 / 133 (7.52%)
    7 / 67 (10.45%)
         occurrences all number
    13
    8
    Musculoskeletal pain
         subjects affected / exposed
    10 / 133 (7.52%)
    6 / 67 (8.96%)
         occurrences all number
    12
    6
    Pain in extremity
         subjects affected / exposed
    9 / 133 (6.77%)
    4 / 67 (5.97%)
         occurrences all number
    10
    5
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    15 / 133 (11.28%)
    6 / 67 (8.96%)
         occurrences all number
    20
    8
    Sinusitis
         subjects affected / exposed
    7 / 133 (5.26%)
    2 / 67 (2.99%)
         occurrences all number
    9
    2
    Upper respiratory tract infection
         subjects affected / exposed
    18 / 133 (13.53%)
    9 / 67 (13.43%)
         occurrences all number
    28
    12
    Urinary tract infection
         subjects affected / exposed
    9 / 133 (6.77%)
    8 / 67 (11.94%)
         occurrences all number
    10
    10
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    30 / 133 (22.56%)
    12 / 67 (17.91%)
         occurrences all number
    52
    14
    Hypokalaemia
         subjects affected / exposed
    13 / 133 (9.77%)
    4 / 67 (5.97%)
         occurrences all number
    16
    5

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    21 Dec 2016
    Study schema related to study drug discontinuation has been clarified with regards to discontinuation for toxicity and treatment beyond progression. Safety, pharmacokinetic, and immunogenicity endpoints for the study have been clarified. Bone scan requirements have been clarified with regards to frequency. On the basis of updated clinical data regarding the atezolizumab half-life of 27 days, the abstinence period and when to use of live vaccine was revised. Tumor specimen requirements have been clarified. Inclusion criteria related to local laboratory assessments for screening have been clarified. Exclusion criteria related to cardiopulmonary dysfunction, patients with severe infection, leptomeningeal disease, washout period of prior anti-cancer therapy has been added/revised. The unblinding of treatment assignment at the patient level for non-safety reasons has been clarified with regards to when this is permitted. The recalculation of the trastuzumab emtansine dose at every cycle based on a patient’s weight has been clarified. The frequency and type of tumor assessments to be performed after the screening period have been specified. On the basis of a review of clinical data, Epstein Barr virus testing is no longer required and has been removed from the protocol. The alpha spending function to be used for testing the primary efficacy endpoint PFS to account for the conduct of one interim analysis was changed from a gamma function with parameter -8 to a gamma function with parameter -1.
    09 Aug 2017
    The interim analysis for PFS has been removed. The number of PFS events for the primary PFS analysis has been increased from 95 to 115. The first analysis of OS will be performed at the time of the primary PFS analysis. Another update for OS will be performed at approximately 12 months after the primary PFS analysis. The final OS analysis will be performed at approximately 24 months after the primary PFS analysis or when ~50% OS events from 200 patients can be obtained, whichever occurs first. The Sponsor may consider additional OS updates beyond 24 months after primary PFS analysis if more mature OS data are requested by the Health Authority. The changes allow for a better understanding of the therapeutic effects of the experimental treatment on OS and provide more mature data for benefit-risk assessment with the additional follow-up period for survival data. The assumed median PFS time for the control arm, trastuzumab emtansine plus placebo, has been changed from 9.6 months (observed in EMILIA study) to 6.2 months (observed in TH3RESA study) to reflect the observed prior treatment demographics of patients enrolled in the study. The estimated time for primary PFS analysis has been changed from approximately 19−21 months after first patient enrolled to approximately 15−17 months after first patient enrolled, due to the updated assumption of median PFS time for the control arm and the updated number of events for primary PFS analysis. The pregnancy reporting process has been clarified and the safety risks for trastuzumab emtansine and atezolizumab have been updated. Brain assessment, brain computed tomography/magnetic resonance imagining requirements, and event reporting for hospitalization have been clarified and the reporting of the term "sudden death" has been updated to also require the presumed cause of death. The process for reviewing and handling protocol deviations has been updated per internal standard operating procedures.
    28 Feb 2018
    Updated information regarding the independent data monitoring committee (iDMC) recommendation and the Sponsor's decision to unblind treatment assignment. Modifications were made to the information regarding the frequency of tumor assessments and collection of tumor assessment scans following PFS analysis. Placebo administration was removed for patients randomized to Arm A. Imaginng data used for tumor assessment would no longer be collected by the Sponsor. For participants in Arm A, the thyroid function test woul no longer be perfromed and PK and ATA samples would not be collected. Language regarding post-trial access was modified to align with current standardsd. The time period for storage of tumor tissue samples was clarified. Language was added to clarif the use of samples after withdrawl of participant consent. Language was added and modified to align with the most recent Investigator's Brochure. eCRF use of recording of death attributed to progression of metastatic breast cancer was clarified. Safety analyses and criteria related to PFS assessed using the Immune-Modified RECIST was amended to be consistent with the SAP.
    30 Nov 2018
    Blood samples would no longer be collected for the analysis of trastuzumab emtansine and atezolizumab PK and ATAs. Blood samples for biomarker analyses would no longer be collected. Text was added to clarify that the Sponsor may decide to terminate the study after the OS analysis that was planned for 12 months after the primary PFS analysis and the duration of the study ws clarified to be a maximum of 40 months. The option to conduct OS analysis beyond 24 months after the primary analysis was removed. Inclusion criteria was modified to specify when women must refrain from donating eggs. Instructions regardng participant withdrawl from the Roche Bosample Repositiory after site closure was modified to indicate that the investigator must inform the Sponsor of participant withdrawl. The lists of risks for atezolizumab and guidelines for managing participants who experienced atezolizumab AEs were revised to include nephritis. Language was added for consistency with Roche's current data retention policy.
    25 Oct 2019
    Background information regarding atezolizumab was updated. The list of atezolizumab risks was updated as well as the guidelines for managing participants who experience-atezolizumab AEs to include myositis. "Immune-related" was changed to "Immune-mediated" when describing events associated with atezolizumab. To address a request by the French National Agency for the Safety of Medicines and Health Products (ANSM), language regarding atezolizumab risks was revised to remove the description and management guidelines for systemic immune activation and to add descriptions and management guidelines for hemophagocytic lymphohistiocytosis and macrophage activation syndrome. The medical monitor changed. Language was updated to indicate that therapeutic or elective abortions were not considered AEs and that the underlying toxicity should be reported as a seriours AE. Language was added to clarify that all abortions needed to be reported on the Clinical Trial Pregnancy Reporting Form paper. Language was added for consistency with Roche's current data retention policy, and to indicate that the study would comply wih applicable local, regional. and national laws. Language was revised to clarify that the datd from this study would not be limited to 2 clinical trail registries and that redacted Clinical Study Reports and other summary reports were available upon request. To address a request by the French ANSM, the atezolizumab AE management guidelines were revised to add laboratory and cardiac imaging abnormalities as signs or symptoms that are suggestive of myocarditis.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 09:48:55 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA